The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/111709
BASi ��� West Lafayette, IN www.basinc.com ��� PH: (765) 463-4527 Key locations: Mount Vernon, IN and West Lafayette, IN Contact: Frances A. Leath ��� fleath@basinc.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Bioanalytical, Clinical, Preclinical SERVICES & CAPABILITIES: BASi offers research services along the entire drug development continuum, including drug discovery (ADME, Neuroscience), bioanalytical (large and small molecule), preclinical toxicology, and pharmaceutical analysis (including in vitro bioequivalence). THERAPEUTIC AREAS: Analgesic, cardiovascular, diabetes, infectious disease, oncology, Neurology, and CNS KEY INDUSTRY PARTNERS: Pinnacle Technology of Lawrence, KS and Data Sciences International (DSI), the global leader in implantable telemetric physiological monitors ��We are very pleased to be recognized as a leader in our industry for innovation. Our highly skilled employees strive every day to find new ways to solve increasingly difficult problems in drug development. At BASi, we pursue innovation because it is empowering for our clients and our employees. When we pursue innovation, we advance the boundaries of what is possible for everyone.�� �� Jacqueline M. Lemke, interim president and CEO, VP of finance and CFO BRI Biopharmaceutical Research Inc. ��� Vancouver, BC www.bripharm.com ��� (604) 432-9237 x225 Key locations: Vancouver, BC, Canada Contact: David Kwok or Clara Faan ��� dkwok@bripharm.com or cfaan@bripharm.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Bioanalytical, Clinical, Preclinical SERVICES & CAPABILITIES: GLP Bioanalytical assays (LCMSMS, ELISA, Hybridization, RT-PCR) supported by Thermo-Watson��� LIMS, In vitro drug metabolism assays (P450 / UGT phenotyping, inhibition, induction), In vitro ADME assays (protein binding, mechanistic P450 TDI kinetics, covalent binding, metabolite profile 14C-labeled drugs), In vitro cancer cell line efficacy assays, In vivo (AAALAC accredited) rodent PK, acute tox and tumor xenograft efficacy (subcutaneous and renal-capsule) models THERAPEUTIC AREAS: Prostate cancer cell biology, antitumor pharmacology, and patient-derived tumor xenografts KEY INDUSTRY PARTNERS: Oncograph��� Therapeutics Inc. (a patient-derived xenograft cancer biology contract research company), In vitro ADMET��� ( a primary human hepatocyte in vitro drug metabolism contract research company) ��For nearly two decades, BRI has become recognized by its pharma and biotech clients for providing fit-for-purpose bioanalytical and DMPK studies supporting IND-enabling preclinical and clinical development. On behalf of our study teams and management at BRI, I am very pleased to have contributed to our clients�� successful milestones over the years.�� �� David Kwok, CEO Charles River ��� Wilmington, MA www.criver.com ��� (781) 222-6000 or (877) CRiver1 key locations: Canada, France, Germany, Ireland, Italy, Japan, U.S., and United Kingdom askcharlesriver@crl.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Bioanalytical, Preclinical SERVICES & CAPABILITIES: Preclinical services (toxicology and safety pharmacology), research models and services, pathology services, laboratory sciences, agrochemical and animal health product development, and biopharmaceutical testing and manufacturing THERAPEUTIC AREAS: Cardiovascular, endocrine/metabolic, oncology, skeletal disease, central nervous system, inflammation, ophthalmology, and vaccines/cell therapy/biosimilars KEY INDUSTRY PARTNERS: Charles River partners with pharmaceutical and biotechnology companies, government agencies, and leading academic institiutions around the globe to accelerate their research and drug development efforts. ��With the industry at an inflection point with regard to outsourcing, providing high quality scientific expertise, reliable client service, and innovative solutions gives clients the confidence they need to outsource their drug development programs to a CRO like Charles River. We are pleased that our clients recognize Charles River��s industry leadership in these areas with this award.�� �� James Foster, CEO The CRO Leadership Awards 2013 23